Pediatric Praziquantel Consortium

Publication: Relative bioavailability of two novel orally dispersible tablet formulations of praziquantel

14 January 2019

In January 2019, researchers from the Pediatric Praziquantel Consortium published the results of two Phase I...

Pediatric Praziquantel Consortium successfully completed Phase II in Ivory Coast

10 December 2018

The important milestone of Last Patient Last Visit (LPLV) in the clinical Phase II trial was achieved on...

A story of schistosomiasis infection in Ghana

A story of schistosomiasis infection in Ghana.
Video credit: Shelly Xie


Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more


Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more